

Under the Auspices of SIE - Società Italiana di Ematologia

6th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

ROME, September 29th - October 2nd, 2013

Chairmen: **F. Lo-Coco, M.A. Sanz**
Honorary President: **F. Mandelli**

www.apl2013.com

6th INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA

ROME, September 29th - October 2nd, 2013

Dear Colleague,

we are pleased to announce the 6th International Symposium on Acute Promyelocytic Leukemia will be held in Rome on September 29 - October 2, 2013 (www.apl2013.com).

This conference has long since become a traditional, well established meeting that gathers together renowned scientists, from all over the globe. In fact, basic science, translational and clinical experts will update the audience on most recent advances related to both laboratory and clinical research in APL and related fields (differentiation treatments, targeted therapy, oncogenic signaling, minimal residual disease etc.).

In addition to clinical and research update on unpublished work, there will be an educational session to address the issues related to diagnostics and management of the disease. Furthermore this conference will host a forum on international collaboration and projects for implementing clinical networking on APL and available treatment resources in developing countries. Finally, the symposium offers a great opportunity for young investigators interested in the field to present their work in dedicated oral and poster session.

We are delighted to welcome you to the Eternal City!

Francesco Lo-Coco
Symposium co-chairman

Miguel A. Sanz
Symposium co-chairman

FACULTY

Lionel Adès	France	Eva Lengfelder	Germany
Myriam Alcalay	Italy	Giuseppe Leone	Italy
Sergio Amadori	Italy	Timothy Ley	USA
Giuseppe Avvisati	Italy	Francesco Lo-Coco	Italy
Nancy Berliner	USA	Bob Löwenberg	The Netherlands
Massimo Breccia	Italy	Franco Mandelli	Italy
Alan K. Burnett	UK	Vikram Mathews	India
Mammen Chandy	India	Wilson H. Miller	Canada
Sai-Juan Chen	China	Saverio Minucci	Italy
Christine Chomienne	France	Pau Montesinos	Spain
Hugues de Thé	France	Pellegrino Musto	Italy
Laurent Degos	France	Clara Nervi	Italy
Gerhard Ehninger	Germany	Alberto Orfao	Spain
Elihu Estey	USA	Pier Paolo Pandolfi	USA
Anna Falanga	Italy	Fabrizio Pane	Italy
Brunangelo Falini	Italy	Pier Giuseppe Pelicci	Italy
Pierre Fenaux	France	Uwe Platzbecker	Germany
Felicitto Ferrara	Italy	Eduardo M. Rego	Brasil
Francesco Grignani	Italy	Jacob R. Rowe	Israel
David Grimwade	UK	Giuseppe Saglio	Italy
Syed Khizer Hasan	India	Valeria Santini	Italy
Jiong Hu	China	Miguel A. Sanz	Spain
Harry Iland	Australia	Jaime Sanz	Spain
Richard Larson	USA	Richard Schlenk	Germany
Roberto Latagliata	Italy	Martin S. Tallman	USA
Soren Lehmann	Sweden	Christian Thiede	Germany

2.00 pm Registration opens

3.00 - 4.00 pm **PRE-MEETING SYMPOSIUM - Diagnostic tools and targeted therapies in myeloid malignancies**
Chairs: **P. Musto, F. Pane**

Prognostic classification and response monitoring using molecular diagnostics in AML: current results and developments
C. Thiede

New euroflow tools for the immunophenotypic characterization of acute promyelocytic leukemia at diagnosis and during follow-up
A. Orfao

Molecular pathways and targeted therapies in myelodysplasia
V. Santini

4.00 - 4.30 pm *Coffee break*

4.30 - 5.45 pm **EDUCATIONAL SESSION - Biology, diagnosis and management of APL**

Pathogenesis, diagnosis and monitoring
F. Lo-Coco

Front-line therapy
M.A. Sanz

Therapy of relapse
P. Fenaux

6.00 - 6.20 pm **Opening Ceremony**

6.20 - 7.20 pm **KEYNOTE LECTURE**
Introducer: **A. Keating**
The APL Genome - *T. Ley*

7.20 pm **Welcome Cocktail**

9.00 - 10.10 am

PLENARY SESSION I - Experimental models and targeted therapy

Chairs: **F. Grignani, W.H. Miller**

Molecular basis for APL eradication by the retinoic
arsenic combination
H. de Thé

Targeted therapy: the new lease of life for conquering leukemia
S.J. Chen

Deconstructing the molecular genetics of Acute
Promyelocytic Leukemia and its therapeutic implications
P.P. Pandolfi

10.10 - 10.30 am

Coffee break

10.30 - 11.40 am

**PLENARY SESSION II - Tracking leukemia stem cells and
Minimal residual disease**

Chairs: **C. Thiede, G. Saglio**

MRD in APL: implications of molecular and cellular methods
C. Chomienne

Tracking therapy-resistant clones
D. Grimwade

Leukemia-initiating cells in APL
P.G. Pelicci

11.45 am - 1.00 pm **SIMULTANEOUS ORAL SESSION I**[PLENARY](#)**Oncogenic signalling**Chair: **C. Nervi**

- CO01 Oncogenic disruption of promyelocytic leukemia nuclear bodies in APL cells results in defects in DNA double strand breaks sensing and repair
Cilli D., Nervi C., di Masi A. (*Roma, Latina - Italy*)
- CO02 ATRA activates APL leukemic cells maturation by promoting PU.1 expression and reinstating PTEN function
Noguera N.I., Angelini G., Gaur G., Catalano G., Pireda L., Bruno A., Amadori S., Lo-Coco F. (*Roma - Italy, Rosario - Argentina*)
- CO03 Potential role of the Insulin/Insulin-like growth factor axis in ATRA resistance of APL cells in the obesity context
Durfort T., Mazzarella L., Pelicci P.G. (*Milano - Italy*)
- CO04 A dual role for HDAC1: onco-suppressor in tumorigenesis, oncogene in tumor maintenance
Santoro F., Botrugno O.A., Dal Zuffo R., Pallavicini I., Matthews G.M., Cluse L., Barozzi I., Senese S., Fornasari L., Moretti S., Altucci L., Pelicci P.G., Chiocca S., Johnstone R.W., Minucci S. (*Milano, Napoli - Italy, Melbourne - Australia*)

- CO05 Activation of a PML/P53/senescence axis underlies therapy-triggered APL eradication
Ablain J., Soilihi H., Rice K., Minucci S., de Thé H. (*Paris - France, Milano - Italy*)

11.45 am - 1.00 pm **SIMULTANEOUS ORAL SESSION II**[SALA TIZIANO](#)**Front-line therapy I**Chair: **F. Ferrara**

- CO06 Arsenic trioxide (ATO) or ATRA for consolidation treatment of standard risk non elderly newly diagnosed APL - second interim analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group
Ades L., Chevret S., Raffoux E., Pigneux A., Thomas X., Bordessoule D., Vey N., Guerci A., Lamy T., Récher C., Lambert J.F., Tournilhac O., Pautas C., Cahn J.Y., Bron D., Delaunay J., Deconinck E., Quesnel B., de Botton S., Stamatoullas A., Chomienne C., Dombret H., Degos L., Fenaux P. (*French Belgian Swiss APL Group*)
- CO07 A Phase III randomized trial (S0521) of maintenance versus observation for patients with previously untreated low/intermediate risk acute promyelocytic leukemia
Coutre S.E., Othus M., Powell B., Willman C.L., Stock W., Paietta E., Levitan D., Wetzler M., Attar E.C., Altman J.K., Gore S.D., Maher T., Kopecky K.J., Tallman M.S., Larson R.A., Appelbaum F.R. (*Stanford, Wake Forest, Albuquerque, Chicago, Bronx, Buffalo, Boston, Baltimore, New York, Seattle - USA*)

- CO08 Result of APL Treatment with Arsenic Trioxide as First Line: More Experience of Center and More Consolidation Improve Results
Ghavamzadeh A., Alimoghaddam K., Jalili M., Rostami S., Ghaffari S.H., Jahani M., Mousavi S.A., Bahar B., Vaezi M., Esfandbod M. (Tehran, Iran)
- CO09 Optimal management of APL in developing countries - Are we optimized yet?
Kumar K.S., Badarkhe G. V., Nath U.K., Ray S.S., P. Chakraborty, Chaudhuri U. (Kolkata - India)
- CO10 Patterns of immune reconstitution in patients with acute promyelocytic leukemia treated with single agent arsenic trioxide and its impact on time to molecular remission
Abu Alex A., Ganesan S., Chendamarai E., Lakshmi K.M., Balasubramanian P., George B., Srivastava A., Mathews V. (Vellore - India)

1.00 - 2.15 pm *Lunch*2.15 - 3.15 pm **PLENARY SESSION III - Management of APL in developing countries**Chairs: **N. Berliner, B. Löwenberg**Challenges and strategies to improve the outcome of APL in developing countries
*E.M. Rego*Translating the APL success story: how do we ensure that more patients with APL in developing world are treated correctly
*M. Chandy*Management of APL in Tunisia
*R. Jeddi*3.15 - 3.30 pm *Coffee break*3.30 pm - 4.30 pm **SIMULTANEOUS ORAL SESSION III**
Micro RNA and next-generation sequencing
Chair: **V. Mathews**[PLENARY](#)CO11 Functional role and regulation of miRNA let-7c: an additional and novel molecular target for therapeutic intervention in AML
Pelosi A., Sagrestani G., Battisti T., Lavorigna S., Calabretta B., Lo-Coco F., Rizzo M.G. (Roma - Italy, Philadelphia - USA)CO12 Differential expression of a large microRNA gene cluster on chromosome 14q32 in acute promyelocytic leukaemia and its association with PML breakpoint
Brown C.M.S., Agapiou D., Catalano A., Yang S., Collins M., Iland H.J. (Sydney, Melbourne - Australia)

CO13 Argonaute 2 contribution to the gene expression program driving human myeloid differentiation of Acute Myeloid Leukemia cells
Iosue I., Quaranta R., Masciarelli S., Fontemaggi G., Ottone T., Divona M., Padula F., Lo-Coco F., Nervi C., Fazi F. (*Latina, Roma - Italy*)

CO14 Whole-exome sequencing data analysis of therapy related APL patients
Russo A., Bodini M., Ottone T., Hasan S.K., Lavorgna S., Lo Coco F., Luzi L., Riva L., Pelicci P.G. (*Milano, Roma - Italy*)

3.30 pm - 4.30 pm **SIMULTANEOUS ORAL SESSION IV** [SALA TIZIANO](#)
Early death and diagnostics
Chair: **B. Falini**

CO15 Ultra rapid molecular detection of the PML-RARA fusion transcripts by Retro-Transcription Loop Mediated Amplification (RT-QLAMP) reaction on the semi-automatic Liaison IAM instrument
D'Agostini E., Rigo F., Mesturini R., Rizzo G., Montrasio C., Minnucci G., Amicarelli G., Colotta F., Divona M., Lo-Coco F. (*Gerenzano, Roma - Italy*)

CO16 Molecular characterization by miRNA expression profiling, deregulation of miRNAs may identify patients at risk of early death
Kota V., Jillella A., Rojiani A., Arellano M., Kolhe R. (*Georgia - USA*)

CO17 Early deaths (ED) in APL in France: A retrospective study in 399 patients (pts)
Rahme R., Thomas X., Recher C., Vey N., Delaunay J., Deconinck E., Bordessoule D., Micol J.B., Stamatoullas A., Mariette C., Pautas C., Bories P., Marolleau J.P., Hunault-Berger M., Fegueux N., Raffoux E., Dombret H., Chevret S., Degos L., Fenaux P., Ades L. (*French Belgian Swiss Apl Group*)

CO18 A successful model to decrease early and preventable deaths in Acute Promyelocytic Leukemia (APL) through the use of a simplified algorithm and expert support in experienced as well as smaller leukemia treatment centers in the US
Jillella A., Kolhe R., Awan F., Pantin J., Kota V. (*Georgia - USA*)

4.30 - 6.00 pm *Poster Viewing*

8.45 - 10.00 am

SIMULTANEOUS ORAL SESSION V[PLENARY](#)**Prognostic factors and therapy-related leukemia**Chair: **D. Grimwade**

- CO19 CD56 expression is one of the unfavourable prognostic factors for acute promyelocytic leukemia (APL) patients: Long-term follow-up results of the Japan Adult Leukemia Study Group (JALSG) APL 97 study
 Takeshita A., Ono T., Ohnishi K., Kishimoto Y., Kiyoi H., Okada M., Yamauchi T., Emi N., Fujita H., Horikawa K., Matsuda M., Shinagawa K., Monma F., Ohtake S., Nakaseko C., Takahashi M., Kimura Y., Iwanaga M., Asou N., Miyawaki S., Miyazaki Y., Naoe T. (Japan Adult Leukemia Study Group)

- CO20 Np73/TAp73 expression ratio is associated with treatment outcome of patients with acute promyelocytic leukemia and cooperate with resistance to drug-induced apoptosis in a bone marrow lentiviral transduction model
 Lucena-Araujo A.R., Kim H.T., Scheucher P.S., Krause A., dos Santos G.A., Thomé C., Jacomo R.H., Melo R.A., Bittencourt R., Pasquini R., Pagnano K., Fagundes E.M., de Lourdes Chauffaille M., Chiatton C.S., Ruiz-Argüelles G., Undurraga M.S., Martinez L., Kwaan H.C., Gallagher R., Niemeyer C.M., Schrier S.L., Tallman M.S., Grimwade D., Ganser A., Berliner N., Ribeiro R.C., Lo-Coco F., Löwenberg B., Sanz M.A., Rego E.M. (Ribeirao Preto, Brazil, Boston, USA, Recife, Porto Alegre, Curitiba, Campinas, Bel Horizonte Sao Paulo - Brazil, Puebla - México, Santiago - Chile, Montevideo - Uruguay, Chicago, New York - USA, Freiburg - Germany, Stanford - USA, London - UK, Hannover

- Germany, Boston - USA, Memphis - USA, Roma - Italy, Rotterdam - Netherlands, Valencia - Spain)

- CO21 Characteristics and outcome of patients with secondary and therapy-related acute promyelocytic leukemia treated with the PETHEMA protocols
 Montesinos P., Salamero O., Rayón C., Rivas C., Holowiecka A., García-Boyer R., González J.D., Ribera J.M., Pérez-Encinas M., González J., González M., Esteve J., De la Serna J., Brunet S., Pedro C., Negri S., Milone G., Fazio P., Herrera P., Amutio E., Rubio V., Capote F.J., Arnan M., Mateos M.C., Sanz M.A. (On behalf of the PETHEMA, PALG, and GATLA cooperative groups)
- CO22 Therapy-related acute promyelocytic leukemia: a systematic review
 Rashidi A., Fisher S.I. (Norfolk - USA)

8.45 - 10.00 am

SIMULTANEOUS ORAL SESSION VI[SALA TIZIANO](#)**In vitro and in vivo APL models**Chair: **H. de Thé**

- CO23 The PML protein participates in telomere surveillance in normal and TERT-deficient human cells
 Marchesini M., Matocci R., Marinelli C., Tasselli L., Cambiaghi V., Faretta M., Pelicci P.G., Grignani F. (Perugia, Milano - Italy)

- CO24 Modelling the influence of diet on APL identifies Insulin-Growth Factor 1 as a central mediator and provides a mechanistic rationale for therapeutic weight loss
Mazzarella L., Durfort T., Rani P., Pelicci P.G. (Milano - Italy)
- CO25 Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukaemia treated with arsenic trioxide: Insights into mechanisms of resistance to arsenic trioxide
Chendamarai E., Ganesan S., Abu Alex A., Nair S., Kamath V., Nellickal A.J., Lakshmi K.M., Balasubramanian P., David S., George B., Viswabandya A., Abraham A., Srivastava A., Mathews V. (Vellore - India)
- CO26 Induction of senescence underlies APL cure by retinoic acid
Rice K., Ablain J., Soilihi H., Berthier C., Minucci S., de Thé H. (INSERM)
- CO27 Selective inhibition of *rar α* 1, *rar α* 2 and *pml/rar α* in apl cells; effects on proliferation and granulocytic differentiation
Gianni M., Terao M., Kurosaki M., Zanetti A., Garattini E. (Milano - Italy)

- 10.00 - 11.00 am **PLENARY SESSION IV - Early death in APL: data from real world**
Chairs: **J.R. Rowe, M.A. Sanz**
- An update from the Swedish registry has early death rates in APL improved?
S. Lehmann
- Early death in APL: real world data and the way forward
M.S. Tallman
- Epidemiology and outcome of acute promyelocytic leukemia:
A pan Canadian population-based analysis
M. Seftel
- 11.00 - 11.20 am Coffee break
- 11.20 am - 12.00 pm **PLENARY SESSION V - The APL coagulopathy**
Chairs: **G. Avvisati, H. Iland**
- Molecular basis of the APL coagulopathy
A. Falanga
- Incidence and risk factors for thromboembolic complications in APL
P. Montesinos

12.00 - 1.00 pm

PLENARY SESSION VI - Oncogenic signalling and epigenetics

Chairs: **M. Alcalay, P.P. Pandolfi**

The epigenetic role of microRNA-223 in normal hematopoiesis and acute myeloid leukemias
C. Nervi

A novel role of chromatin modulation in retinoid - resistant APL
W.H. Miller

Chromatin alterations in leukemogenesis: same players, same roles?
S. Minucci

1.00 - 2.00 pm

Lunch

2.00 - 3.20 pm

PLENARY SESSION VII - Update on first line therapy (I)

Chairs: **L. Degos, F. Mandelli**

The GIMEMA pathway to the cure of APL
G. Avvisati

Improvements with risk-adapted PETHEMA protocols in newly diagnosed APL
M.A. Sanz

Combined ATRA and arsenic treatment as front-line therapy for APL: experience from China
J. Hu

The Australasian Leukaemia and Lymphoma Group APML4 trial - update on APL treatment down under
H. Iland

3.20 - 3.35 pm

Coffee break

3.35 - 5.00 pm

PLENARY SESSION VIII - Update on first line therapy (II)

Chairs: **S. Amadori, M.S. Tallman**

Strategies to improve clinical outcome of upfront therapy with arsenic trioxide without increasing myelosuppression and maintaining low toxicity
V. Mathews

Clinical trials in diseases with high cure rates: treatment of APL without chemotherapy as an example
E. Estey

An update of French-Swiss-Belgian trials in newly diagnosed APL
L. Adès

From the UK: less is just as good
A.K. Burnett

8.30 - 9.30 am

PLENARY SESSION IX - Management of relapse and role of stem cell transplantation

Chairs: **A.K. Burnett, G. Ehninger**

Results of the European registry of patients with relapsed APL (PROMYSE)

E. Lengfelder

Role of arsenic trioxide for the management of relapsed APL patients

M. Breccia

Role of stem cell transplantation

J. Sanz

9.30 - 10.30 am

PLENARY SESSION X - APL as a second tumor and t-MN after APL

Chairs: **G. Leone, U. Platzbecker**

tMN in APL patients receiving ATRA and chemotherapy

P. Montesinos

Clinical, pathological, and cytogenetic features of therapy-related acute promyelocytic leukemia

R.A. Larson

APL secondary to non-malignant disorders

S.K. Hasan

10.30 -10.45 am

Coffee break

10.45 - 11.30 am

SIMULTANEOUS ORAL SESSION VII[PLENARY](#)**Front-line therapy II**Chair: **L. Adès**

- CO28 Incidence and risk factors for thrombosis in 921 patients with acute promyelocytic leukemia registered in the PETHEMA LPA2005 & LPA2012 trials
Rodríguez-Veiga R., Montesinos P., Holowiecka A., Vellenga E., Rayón C., Rivas C., De la Serna J., Salamero O., Ribera J.M., Brunet S., González-Campos J., De Lisa E., Krsnik I., Fazio P., Pérez C., Pérez-Encinas M.M., Rubio V., Bergua J., González-San Miguel J.D., Paluszewska M., Milone G., Esteve J., Lowenberg B., Sanz M.A.
(On behalf of the PETHEMA, HOVON, PALG, and GATLA cooperative groups)
- CO29 Long term health related quality of life in patients with acute promyelocytic leukemia
Efficace F., Breccia M., Avisati G., Cottone F., Vignetti M., Mandelli F., Lo Coco F.
(Roma - Italy)
- CO30 13 year follow-up of liposomal ATRA monotherapy for newly-diagnosed APL
Jain P., Kantarjian H., Estey E., Pierce S., Lopez-Berestein G., Ravandi F. *(Houston, Seattle - USA)*
- CO31 Evaluation of synergism between arsenic trioxide and bortezomib in acute promyelocytic leukemia
Ganesan S., Chendamarai E., Abu Alex A., Balasundaram N., Kumar Palani H., David S.,

Jayandharan G.R., Ahmed R., Abraham A., Viswabandya A., George B., Srivastava A., Mathews V. *(Vellore - India)*

10.45 - 11.30 am

SIMULTANEOUS ORAL SESSION VIII[SALA TIZIANO](#)**Experimental therapies and drug resistance**Chair: **E. Rego**

- CO32 The therapeutic effect of genistein in acute promyelocytic leukemia involves inhibition of casein kinase II and activation of the Ikaros tumor suppressor
Dovat S., Song C., Payne K.J. *(Hershey, Loma Linda - USA)*
- CO33 Andrographolide has anti-leukemic activity in acute promyelocytic leukemia (APL) via induction of reactive oxygen species (ROS) dependent apoptosis and not differentiation): molecular mechanisms and interrogation of signaling pathways
Yang S., Altman J.K., Ding B., Tom A., Wu B., Prachand S., Platanias L.C., Gordon L.I.
(Chicago - USA)
- CO34 Antileukemic efficacy and mechanism of action of lithium chloride in APL
Zassadowski F., Pokorna K., Ferre N., Chourbagi O., Poupon J., Chopin M., Fenaux P., Ades L., Padua R.A., Pla M., Chomienne C., Cassinat B. *(Paris - France, Prague - Czech Republic, Bobigny - France)*

CO35 Environment mediated drug resistance to arsenic trioxide in acute promyelocytic leukemia
Ganesan S., Abu Alex A., Chendamarai E., Kumar Palani H., Balasundaram N., David S., Jayandharan G.R., Ahmed R., Abraham A., Viswabandya A., George B., Srivastava A., Mathews V. (*Vellore - India*)

11.30 am - 1.10 pm **PLENARY SESSION XI - Pediatric and elderly APL**

Chairs: **E. Estey, R. Schlenk**

Pediatric and elderly APL: the French-Belgian-Swiss experience
L. Adès

Results of the International APL trial in children
A.M. Testi

Acute promyelocytic leukemia in the elderly: beyond the age
R. Latagliata

Characteristics and outcomes of elderly patients with acute promyelocytic leukaemia registered in the PETHEMA trials
D. Martínez-Cuadrón

1.10 pm **Conclusive remarks**
F. Lo-Coco

IN VITRO AND IN VIVO MODELS

P01
 INHIBITORY EFFECT OF THE ADRENOMEDULLIN SYSTEM IN A HUMAN PROMYELOCYTIC CELL LINE
Bridi D., Di Liddo R., Gottardi M., Grandi C., Conconi M.T., De Angeli S. (*Padova, Treviso - Italy*)

P02
 HEMATOPOIETIC PROGENITOR CD34+ CELLS, ACUTE MYELOID LEUKAEMIA KG1 CELLS AND MATURE NEUTROPHILS AS MODELS FOR HUMAN HEMATOPOIETIC CELL DEVELOPMENT
Navakauskiene R., Borutinskaite V., Treigyte G., Savickiene J., Matuzevicius D., Magnusson K.E., Navakauskas D. (*Vilnius - Lithuania, Linköping - Sweden*)

P03
 HSP90 INHIBITION CAUSES APOPTOSIS IN ATO AND ATRA RESISTANT NB4 CELLS IN A PML/RARA INDEPENDENT MANNER
Noguera N.I., Ashraf S., Borgia L., Piras E., Gaur G., Garza E., Angelini G., Batistini L., Lo-Coco F. (*Roma - Italy, Rosario - Argentina*)

P04
 ANALYSIS OF RXRA FUNCTION IN APL SUGGESTS A NEW MODEL FOR RA- AND ARSENIC-INDUCED DIFFERENTIATION
Vitaliano-Prunier A., Haftermeyer J., Ablain J., Pérès L., de Thé H. (*INSERM*)

BIOLOGY AND MINIMAL RESIDUAL DISEASE

P05

GENOME-WIDE METHYLATION ANALYSIS OF MYELOID PROGENITORS IN ACUTE PROMYELOCYTIC LEUKEMIA AT DIAGNOSIS AND AT HEMATOLOGICAL REMISSION, IN COMPARISON TO NORMAL BONE MARROW

Santana-Lemos B.A., Paiva H.H., Colli L.M., Gouvea-Lima A.S., Araújo A.G., Rego E.M. (Ribeirão Preto - Brazil)

P06

NEWLY DIAGNOSED ADULT AML AND MPAL PATIENTS FREQUENTLY SHOW CLONAL RESIDUAL HEMATOPOIESIS

Fernandez-Gimenez C., Santos-Silva M.C., López A., Matarraz S., Jara-Acevedo M., Gutierrez L., Sánchez M.L., Cervero C., Gutierrez O., González N., Salvador-Osuna C., Orfao A. (Salamanca, Cuenca, Valladolid, Teruel, Zaragoza - Spain, Santa Catarina - Brazil)

P07

MONITORING MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS (PTS) WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) TREATED WITH ALL-TRANS-RETINOIC ACID (ATRA) AND ARSENIC TRIOXIDE (ATO)

Melillo L., Minervini M.M., Bodenizza C., Valente D., Cascavilla N. (San Giovanni Rotondo - Italy)

P08

POLYCOMB GROUP (PCG) PROTEIN BMI-1 IS EXPRESSED IN ACUTE PROMYELOCYTIC LEUKEMIA (APL): A SMALL CASE SERIES ILLUSTRATING CLINICAL UTILITY

Moniruddin C., Keichiro M., Akiro K. (Selangor - Malaysia, Hiroshima - Japan)

P09

IDENTIFICATION AND CHARACTERIZATION OF EF413001 AS A DIFFERENTIALLY REGULATED GENE IN THE DIFFERENTIATION OF BLASTS OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) AND IN CD34+ HEMATOPOIETIC PROGENITOR CELLS

Klaumuenzer M., Seifarth W., Fabarius A., Marx A., Ruthardt M., Lengfelder E., Hofmann W.K., Nowak D. (Mannheim, Frankfurt am Main - Germany)

P10

NUCLEOPHOSMIN AND BRG1 MEDIATE A NOVEL MECHANISM OF RETINOIC ACID-RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA

Nichol J.N., Eustache J.H., Galbraith M.D., Espinosa J.M., Miller W.H. (Montréal - Canada, Colorado - USA)

P11

MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN ACUTE PROMYELOCYTIC LEUKAEMIA AND ITS RELATION TO THE CLINICAL OUTCOME

Abdel Hamid T., Gad Alla F., Gafaar E., Raslan H. (Cairo - Egypt)

P12

BASAL LEVEL OF BCR1 AND BCR3 ISOFORMS OF THE FUSION GENE PML-RARα BY RQ-PCR IN PERUVIAN ADULT POPULATION

Dongo-Pflucker K., Cruz-Díaz L.M., Mora-Alfárez P., Ortiz C., Arias-Velásquez A. (Lima - Peru)

P13

T(15;17)(Q22;Q21), T(15;17)(Q22;Q12), OR T(15;17)(Q24;Q21)? A DIAGNOSTIC ENTITY IN SEARCH OF UNANIMITY

Rashidi A., Fisher S.I. (Norfolk - USA)

EARLY DEATH AND COAGULOPATHY

P14

EPIDEMIOLOGY OF MAJOR THROMBOSES IN ACUTE PROMYELOCYTIC LEUKEMIA

Rashidi A., Fisher S.I. (Norfolk - USA)

P15

ACUTE PROMYELOCYTIC LEUKEMIA(APL) PATIENT WITH EXTENSIVE CEREBRAL INFARCTION VERY EARLY AFTER ATRA (ALL-TRANS-RETINOIC ACID) TREATMENT

Tanaka E., Suda T., Inagaki S. (Shonan Kamakura - Japan)

P16

UTILITY AND IMPACT OF EARLY T(15:17) IDENTIFICATION BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN CLINICAL DECISION MAKING FOR PATIENTS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL)

Kolhe R., Rojiani A., Jillela A., Awan F., Arati C., Simmons J., Kota V. (Augusta - USA)

P17

CONGESTIVE HEART FAILURE (CHF) DURING INDUCTION IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENTS

Arati C., Simmons J., Awan F., Anand J., Kolhe R., Kota V. (Georgia - USA)

P18

DO STEROIDS GIVEN PROPHYLACTICALLY ALONG WITH CHEMOTHERAPY DURING INDUCTION FOR ACUTE PROMYELOCYTIC LEUKEMIA (APL) MASK DIFFERENTIATION SYNDROME?

Arati C., Awan F., Simmons J., Anand J., Kolhe R., Kota V. (Georgia - USA)

P19

ACUTE RESPIRATORY FAILURE DURING INDUCTION IN ADULTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

Lanska M., Zak P., Zavrelova A., Radocha J. (Králové - Czech Republic)

P20

OUTCOME EFFECTS OF EARLY ALL-TRANS RETINOIC ACID IN ACUTE PROMYELOCYTIC LEUKEMIA: A MULTICENTRIC STUDY

Rashidi A., Goudar R., Sayedian F., VosJ., Goldin T., Aguilera N.S., Riley M.P., Bayerl M., Fisher S.I. (Norfolk, Morgantown, Charlottesville, Hershey - USA)

P21

DOSE - ADJUSTED ARSENIC TRIOXIDE (ATO) TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WITH SEVERE CHRONIC RENAL FAILURE (CRF)

Firkin F., Khoon Ho W. (Melbourne - Australia)

MANAGEMENT OF RELAPSE

P22

LONG TERM FOLLOW-UP OF EXTRAMEDULLARY RELAPSE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA

Carluccio P., Pastore D., Delia M., Mastice A., Ricco A., Russo Rossi A., Laddaga F.E., Leo M., Specchia G. (Bari - Italy)

P23

LONG-TERM OUTCOME OF 151 PATIENTS WITH RELAPSED APL RECEIVING SECOND-LINE WITH CHEMOTHERAPY- OR ARSENIC TRIOXIDE-BASED REGIMENS

Montesinos P., Martínez-Cuadrón D., Rivas C., Brunet S., González-San Miguel J.D., Rubio V., Pérez C., Manso F., Sánchez-Godoy P., Escoda L., Amutio E., Zijlmans M., Tormo M., González M., Rayón C., Sayas M.J., Ribera J.M., Debén G., Hernández-Martín J.M., Esteve J., Vellenga E., Sanz M.A. (On behalf of the PETHEMA,HOVON, PALG, and GATLA cooperative groups)

P24

EXCELLENT RESPONSE WITH ARSENIC TRIOXIDE USED IN SECOND LINE FOR THE TREATMENT OF A BONE MARROW RELAPSE AND EXTRAMEDULLARY IN ACUTE PROMYELOCYTIC LEUKEMIA

Porrini R., Divona M.D., Ferrari A., Conte E., Neri B., Palmieri R., Montefusco E. (Roma - Italy)

P25

EXTRAMEDULLARY RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA WITH EAR, CUTIS AND CENTRAL NERVOUS SYSTEM INVOLVEMENT SUCCESSFULLY TREATED WITH ATO, ATRA AND INTRATHECAL CHEMOTHERAPY

Tomarchio V., Marchesi F., Berti P., Chiodi F., Cerchiara E., Renzi D., Bianchi A., Avvisati G. (Roma - Italy)

APL MANAGEMENT IN DEVELOPING COUNTRIES

P26

ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF TERTIARY CARE CENTER IN EASTERN INDIA

Badarkhe G.V., Kishore Kumar S., Chakrabarti P., Ray S.S., Nath U.Kr., Chaudhuri U. (Kolkata - India)

P27

ACUTE PROMYELOCYTIC LEUKEMIA WITH UNUSUAL KARYOTYPE

Badarkhe G.V., Kishore Kumar S., Chakrabarti P., Ray S.S., Nath U.Kr., Chaudhuri U. (Kolkata - India)

P28

ERYTHEMA MULTIFORME: AN UNUSUAL ADVERSE EFFECT OF ARSENIC TRIOXIDE

Badarkhe G.V., Kishore Kumar S., Chakrabarti P., Ray S.S., Nath U.Kr., Chaudhuri U. (Kolkata - India)

P29

ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN MALAYS: A SINGLE CENTER EXPERIENCE

Rosline H., Azlan H., Imilia I., Rapiaah M., WZaidah A., Suhair A.A., Selamah G., Ang C.Y., Baba A.A. (Kelantan - Malaysia)

P30

CLINICO HEMATOLOGICAL PROFILE OF APML PATIENTS FROM A TERTIARY CARE CENTER IN EASTERN INDIA

Badarkhe G.V., Kishore Kumar S., Chakrabarti P., Ray S.S., Nath U.Kr., Chaudhuri U. (Kolkata - India)

P31

CHALLENGES IN TREATING ACUTE PROMYELOCYTIC LEUKEMIA IN A ECONOMIC EMERGING COUNTRY: A PARAGUAYAN EXPERIENCE

Ayala-Lugo A., Sánchez S., Salinas V., Negri L., Guggiari P., Samudio A., Ferreira Nizza J., Zarza J. (Asunción - Paraguay)

PROGNOSTIC FACTOR

P32

PROGNOSTIC IMPACT OF MLL5 EXPRESSION LEVELS ON OUTCOME OF PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH ALL-TRANS RETINOIC ACID AND ANTHRACYCLINE-BASED CHEMOTHERAPY: AN INTERNATIONAL CONSORTIUM ON ACUTE PROMYELOCYTIC LEUKEMIA STUDY

Lucena-Araujo A.R., Kim H.T., Jacomo R.H., Melo R.A., Bittencourt R., Pasquini R., Pagnano K., Fagundes E.M., de Lourdes Chauffaille M., Chiattonne C.S., Lima A.S., Ruiz-Argüelles G., Undurraga M.S., Martinez L., Kwaan H.C., Gallagher R., Niemeyer C.M., Schrier S.L., Tallman M.S., Grimwade D., Ganzer A., Berliner N., Ribeiro R.C., Lo-Coco F., Löwenberg B., Sanz M.A., Rego E.M. (Ribeirao Preto - Brazil, Boston - USA, Recife - Brazil, Porto Alegre - Brazil, Curitiba - Brazil, Campinas - Brazil, Belo Horizonte - Brazil, Sao Paulo - Brazil, Puebla - México, Santiago - Chile, Montevideo - Uruguay, Chicago - USA, New York - USA, Freiburg - Germany, Stanford - USA, New York - USA, London - UK, Hannover - Germany, Memphis - USA, Roma - Italy, Rotterdam - Netherlands, Valencia - Spain)

P33

ADVERSE PROGNOSIS IMPACT OF BCR-3 ISOFORM PML-RARA IN THE MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN A HISPANIC POPULATION

Quintana-Truyenque S., Vigil C.E., Arias A., Mora P., Lopez L., Villena M., Vasquez J., Samanez C.A., Casanova L. (Lima - Perú)

P34

INTERNAL TANDEM DUPLICATION OF FLT-3 CONFERS POOR PROGNOSIS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITH THE AIDA PROTOCOLS. LONG-TERM FOLLOW-UP ANALYSIS

Breccia M., Loglisci G., Loglisci M.G., Ricci R., Diverio D., Latagliata R., Foà R., Lo-Coco F. (Roma - Italy)

P35

VALIDATION OF A NEW PROPOSED RELAPSE RISK SCORE (CBC-SCORE) FOR NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA

Breccia M., Serrao A., Loglisci G., Saracino R., Zacheo I., Latagliata R., Lo Coco F. (Roma - Italy)

APL AS A SECOND TUMOR AND T- MN AFTER APL

P36

GENOMIC BREAKPOINT CLUSTERING AT RARA LOCUS IN THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA

Ottone T., Hasan S.K., Voso M.T., Ledda A., Pagoni M., Hubmann M., Lunghi M., Mancini M., Platzbecker U., Lo-Coco F. (Roma - Italy, Cagliari - Italy, Athens - Greece, Munich - Germany, Novara - Italy, Dresden - Germany)

P37

THERAPY RELATED ACUTE PROMYELOCYTIC LEUKEMIA FOLLOWING ETOPOSIDE BASED CHEMOTHERAPY IN NON-SEMINOMATOUS GERM CELL TUMOR

Krishnamani K., Sadashivudu G., Gandhi L.V., Raghunadharao D. (Hyderabad - India)

P38

SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA FOLLOWING DACARBAZINE AND RADIOTHERAPY FOR MALIGNANT MELANOMA-A CASE REPORT

Kumar K.S., Badarkhe G.V., Nath U.K., Ray S.S., Chakraborty P., Chaudhuri U. (Kolkata - India)

P39

PROMYELOCYTIC SARCOMA OF THE STERNUM: A CASE REPORT AND REVIEW OF THE LITERATURE

Thomas X., Cannas G., Kraghel S., Chelghoum Y. (Lyon - France)

P40

SUCCESSFUL PREGNANCY IN APL PATIENTS

Carluccio P., Ricco A., Pastore D., Breccia M., Kropp M.G., Di Bona E., Fabbiano F., Ferrara F., Melillo L., Lo-Coco F., Specchia G. (Bari, Roma, Catanzaro, Vicenza, Palermo, Napoli, S. Giovanni Rotondo - Italy)

PEDIATRIC AND ELDERLY APL

P41

EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA

Abla O. (Toronto - Canada)

P42

A RARE CASE OF T(5;17)(Q35;Q21) VARIANT OF ACUTE PROMYELOCYTIC LEUKEMIA IN ELDERLY PATIENT

Ravelli E., Giudici C., Calzavara E., Saccà V., Borrello A., Alberio F., Martelli M.P., Beghini A., Cairoli C. (Como, Perugia, Milano - Italy)

P43

LATE CARDIOMYOPATHY DUE TO ANTHRACYCLINES AFTER FIRST-LINE THERAPY WITH PETHEMA PROTOCOLS FOR ACUTE PROMYELOCYTIC LEUKEMIA: ASSESSMENT BY MAGNETIC RESONANCE

Rodríguez-Veiga R., Igual B., Montesinos P., Tormo M., Sayas M.J., Linares M., Salvador A., Martínez J., López-Lereu P., Martín G., Sanz J., López-Chulia F., Boluda B., Navarro I., Vera B., Alonso C., Martínez- Cuadrón D., Sanz M.A. (On behalf of the cooperative group PETHEMA)

GENERAL INFORMATION

MEETING VENUE

NH Hotel Vittorio Veneto
Corso d'Italia, 1 - 00198 Roma
Phone +39 06 84951

LANGUAGE

The meeting will be in English with no simultaneous translation.

ITALIAN CME

The Italian Ministry of Health allows no. 11,5 credits for physicians, biologists and technicians.

EUROPEAN CME

The program of the "6TH INTERNATIONAL SYMPOSIUM ON ACUTE PROMYELOCYTIC LEUKEMIA" has been reviewed and approved for CME accreditation by the European Hematology Association CME Unit. The EHA-CME Unit has approved this educational activity for no. 17 CME credits.

BADGE

All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATE

A certificate will be given to all participants at the end of the Meeting.

SLIDES

Slides must be in English. Computer videoprojection will be available in Power Point.
Other requirements should be communicated to the Organizing Secretariat as soon as possible.
Slides should be handed to the slide center one hour before the beginning of the session and collected at the end.

GENERAL INFORMATION

CHANGES

Parts of the program may be changed if necessary.

REGISTRATION FEES

(In Euro - VAT included)

Euro 450,00

Euro 250,00 under 30 years old

Euro 200,00 accepted abstracts' submitters

The registration fee includes:

- Conference kit
- Participation in the scientific sessions
- Attendance Certificate
- Welcome Cocktail
- Coffee breaks
- Lunches

HOTEL REGISTRATION


Triumph C. & C. S.r.l. - Triumph Group

Via Lucilio, 60 - 00136 Rome - Italy

Phone +39 06 355301 - Fax +39 06 35530231

e-mail: booking@gruppotriumph.it

www.triumphgroup.it



NOTES

6th INTERNATIONAL SYMPOSIUM ON
ACUTE PROMYELOCYTIC LEUKEMIA
ROME, September 29th - October 2nd, 2013

SCIENTIFIC SECRETARIAT

Massimo Breccia

Claudia Carissimo

Laura Cicconi

Jonny Di Giandomenico

Syed K. Hasan

Serena Lavorgna

e-mail: segr.apl2013@gmail.com

ORGANIZING SECRETARIAT

Studio E.R. Congressi - Triumph Group

Via Marconi 36 - 40122 Bologna, Italy

Tel. +39 051 4210559 - Fax +39 051 4210174

e-mail: ercongressi@triumphgroup.it

www.ercongressi.it

